Do analysts recommend ENTO or GOSS?

Gossamer Bio has a consensus price target of $5.00, indicating a potential upside of 2,988.33%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gossamer Bio 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20

Does the media refer more to ENTO or GOSS?

In the previous week, Gossamer Bio had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for Gossamer Bio and 1 mentions for Entero Therapeutics. Gossamer Bio's average media sentiment score of 0.93 beat Entero Therapeutics' score of 0.75 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ADXS or ENTO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ADXS or ENTO more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Entero Therapeutics N/A -461.02% -14.72%

Do analysts rate GRCE or ENTO?

Grace Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 172.73%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Grace Therapeutics is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, GRCE or ENTO?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grace Therapeutics N/A N/A -$9.57M -$0.40 N/A Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A

Is GRCE or ENTO more profitable?

Grace Therapeutics' return on equity of -15.58% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -15.58% -14.51% Entero Therapeutics N/A -461.02% -14.72%

Does the media prefer GRCE or ENTO?

In the previous week, Grace Therapeutics had 4 more articles in the media than Entero Therapeutics. MarketBeat recorded 5 mentions for Grace Therapeutics and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.75 beat Grace Therapeutics' score of 0.71 indicating that Entero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GRML or ENTO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, GRML or ENTO?

Entero Therapeutics is trading at a lower price-to-earnings ratio than Greenland Mines Ltd. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenland Mines Ltd. Common Stock N/A N/A -$10.55M -$0.32 N/A Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A

Is GRML or ENTO more profitable?

Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Greenland Mines Ltd. Common Stock N/A -109.40% -98.80% Entero Therapeutics N/A -461.02% -14.72%

Do analysts prefer PYRGF or ENTO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer PYRGF or ENTO?

In the previous week, PyroGenesis Canada and PyroGenesis Canada both had 1 articles in the media. Entero Therapeutics' average media sentiment score of 0.75 beat PyroGenesis Canada's score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Entero Therapeutics (ENTO) Competitors

$5.27 -0.63 (-10.68%)

As of 06/12/2026

Compare

ENTO vs. GOSS, ADXS, GRCE, GRML, and PYRGF

Should you buy Entero Therapeutics stock or one of its competitors? MarketBeat compares Entero Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entero Therapeutics include Gossamer Bio (GOSS), Ayala Pharmaceuticals (ADXS), Grace Therapeutics (GRCE), Greenland Mines Ltd. Common Stock (GRML), and PyroGenesis Canada (PYRGF). These companies are all part of the "pharmaceutical products" industry.

How does Entero Therapeutics compare to Gossamer Bio?

Entero Therapeutics (NASDAQ:ENTO) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Gossamer Bio has a consensus price target of $5.00, indicating a potential upside of 2,988.33%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Gossamer Bio had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for Gossamer Bio and 1 mentions for Entero Therapeutics. Gossamer Bio's average media sentiment score of 0.93 beat Entero Therapeutics' score of 0.75 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Entero Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
Gossamer Bio	-324.82%	N/A	-96.10%

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 3.7% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Entero Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Entero Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
Gossamer Bio	$48.47M	0.78	-$170.37M	-$0.79	N/A

Entero Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

Summary

Gossamer Bio beats Entero Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Entero Therapeutics compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Ayala Pharmaceuticals' return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Entero Therapeutics	N/A	-461.02%	-14.72%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Entero Therapeutics has lower revenue, but higher earnings than Ayala Pharmaceuticals. Entero Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

In the previous week, Entero Therapeutics had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 1 mentions for Entero Therapeutics and 0 mentions for Ayala Pharmaceuticals. Entero Therapeutics' average media sentiment score of 0.75 beat Ayala Pharmaceuticals' score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Entero Therapeutics	Positive

Ayala Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Summary

Entero Therapeutics beats Ayala Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Entero Therapeutics compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Grace Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 172.73%. Given Grace Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Grace Therapeutics is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Grace Therapeutics had 4 more articles in the media than Entero Therapeutics. MarketBeat recorded 5 mentions for Grace Therapeutics and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.75 beat Grace Therapeutics' score of 0.71 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grace Therapeutics' return on equity of -15.58% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-15.58%	-14.51%
Entero Therapeutics	N/A	-461.02%	-14.72%

Grace Therapeutics has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Summary

Grace Therapeutics beats Entero Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to Greenland Mines Ltd. Common Stock?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, Greenland Mines Ltd. Common Stock had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for Greenland Mines Ltd. Common Stock and 1 mentions for Entero Therapeutics. Greenland Mines Ltd. Common Stock's average media sentiment score of 0.93 beat Entero Therapeutics' score of 0.75 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenland Mines Ltd. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%
Entero Therapeutics	N/A	-461.02%	-14.72%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Entero Therapeutics is trading at a lower price-to-earnings ratio than Greenland Mines Ltd. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 11.3% of Greenland Mines Ltd. Common Stock shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Greenland Mines Ltd. Common Stock has a beta of 6.94, meaning that its share price is 594% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

Summary

Greenland Mines Ltd. Common Stock beats Entero Therapeutics on 9 of the 10 factors compared between the two stocks.

How does Entero Therapeutics compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

In the previous week, PyroGenesis Canada and PyroGenesis Canada both had 1 articles in the media. Entero Therapeutics' average media sentiment score of 0.75 beat PyroGenesis Canada's score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PyroGenesis Canada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Entero Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Entero Therapeutics	N/A	-461.02%	-14.72%

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

PyroGenesis Canada has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

Entero Therapeutics has lower revenue, but higher earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	4.28	-$21.12M	-$0.04	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

Summary

Entero Therapeutics beats PyroGenesis Canada on 8 of the 12 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTO vs. The Competition

Export

Metric	Entero Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.37M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-3.12	20.00	24.00	24.42
Price / Sales	N/A	303.75	533.77	123.88
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-2.15	8.32	10.55	6.82
Net Income	-$18.06M	$23.94M	$3.57B	$337.56M
7 Day Performance	-17.01%	1.84%	0.59%	1.16%
1 Month Performance	44.78%	-0.04%	1.55%	3.16%
1 Year Performance	258.28%	44.82%	25.41%	30.60%

Entero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTO Entero Therapeutics	0.0515 of 5 stars	$5.27 -10.7%	N/A	+258.3%	$8.37M	N/A	N/A	9
GOSS Gossamer Bio	2.3495 of 5 stars	$0.18 +13.7%	$5.00 +2,718.5%	-86.9%	$36.61M	$48.47M	N/A	180	Gap Up
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
GRCE Grace Therapeutics	2.6909 of 5 stars	$2.30 -0.4%	$6.00 +160.9%	-22.5%	$35.74M	N/A	N/A	N/A	Upcoming Earnings Gap Up
GRML Greenland Mines Ltd. Common Stock	0.4086 of 5 stars	$0.31 +4.1%	N/A	-81.7%	$35.52M	N/A	N/A	5	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTO) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entero Therapeutics (ENTO) Competitors

ENTO vs. GOSS, ADXS, GRCE, GRML, and PYRGF

How does Entero Therapeutics compare to Gossamer Bio?

Summary

How does Entero Therapeutics compare to Ayala Pharmaceuticals?

Summary

How does Entero Therapeutics compare to Grace Therapeutics?

Summary

How does Entero Therapeutics compare to Greenland Mines Ltd. Common Stock?

Summary

How does Entero Therapeutics compare to PyroGenesis Canada?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTO vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entero Therapeutics (ENTO) Competitors

ENTO vs. GOSS, ADXS, GRCE, GRML, and PYRGF

How does Entero Therapeutics compare to Gossamer Bio?

Do analysts recommend ENTO or GOSS?

Does the media refer more to ENTO or GOSS?

Is ENTO or GOSS more profitable?

Do institutionals and insiders have more ownership in ENTO or GOSS?

Which has better earnings & valuation, ENTO or GOSS?

Which has more volatility and risk, ENTO or GOSS?

Summary

How does Entero Therapeutics compare to Ayala Pharmaceuticals?

Is ADXS or ENTO more profitable?

Do analysts rate ADXS or ENTO?

Do institutionals & insiders believe in ADXS or ENTO?

Which has stronger earnings and valuation, ADXS or ENTO?

Does the media prefer ADXS or ENTO?

Which has more volatility and risk, ADXS or ENTO?

Summary

How does Entero Therapeutics compare to Grace Therapeutics?

Which has better valuation and earnings, GRCE or ENTO?

Do institutionals and insiders believe in GRCE or ENTO?

Do analysts rate GRCE or ENTO?

Does the media prefer GRCE or ENTO?

Is GRCE or ENTO more profitable?

Which has more risk & volatility, GRCE or ENTO?

Summary

How does Entero Therapeutics compare to Greenland Mines Ltd. Common Stock?

Does the media prefer GRML or ENTO?

Is GRML or ENTO more profitable?

Do analysts rate GRML or ENTO?

Which has higher earnings & valuation, GRML or ENTO?

Do insiders and institutionals believe in GRML or ENTO?

Which has more risk and volatility, GRML or ENTO?

Summary

How does Entero Therapeutics compare to PyroGenesis Canada?

Does the media prefer PYRGF or ENTO?

Do analysts prefer PYRGF or ENTO?

Is PYRGF or ENTO more profitable?

Do institutionals & insiders have more ownership in PYRGF or ENTO?

Which has more risk & volatility, PYRGF or ENTO?

Which has higher earnings & valuation, PYRGF or ENTO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTO vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools